News

Apalutamide vs Abiraterone for Deep PSA Response Among Patients With Castration-Sensitive Prostate Cancer

05/25/2023

A retrospective study found that patients with castration-sensitive prostate cancer treated with apalutamide were more likely to experience a deep PSA response than those treated with abiraterone acetate.

A retrospective study found that...

05/25/2023

Oncology

News

No Benefit From Short-Term Androgen Deprivation Added to Dose-Escalated Radiotherapy for Prostate Cancer

05/24/2023

Allison Casey ;

A phase 3 trial found the addition of short-term androgen deprivation to dose-escalated radiotherapy did not improve the overall survival among patients with intermediate-risk prostate cancer.

A phase 3 trial found the...

05/24/2023

Oncology

News

Fluorescent Tracer OTL78 Shows Potential for Prostate Cancer Detection

05/02/2023

Allison Casey ;

According to a first-in-patient study, the prostate-specific membrane antigen (PSMA)-targeted fluorescent tracer OTL78 was well-tolerated and showed potential in improving prostate cancer detection.

According to a first-in-patient...

05/02/2023

Oncology

News

Enzalutamide Plus Abiraterone Not Recommended for Patients With Metastatic Castration-Resistant Prostate Cancer

04/12/2023

According to phase 3 trial results, enzalutamide in combination with abiraterone acetate and prednisone did not prolong overall survival for patients with metastatic castration-resistant prostate cancer in the first-line setting.

According to phase 3 trial...

04/12/2023

Oncology

Conference Coverage

Abiraterone Plus Olaparib Prolonged rPFS, Improved OS Among Patients With Castration-Resistant Prostate Cancer

02/17/2023

Jordan Kadish ;

According to results presented at the 2023 ASCO GU Cancers Symposium, the randomized, double-blind, phase 3 PROpel study found abiraterone acetate plus olaparib prolonged radiographic progression-free survival and improved overall survival...

According to results presented...

02/17/2023

Oncology

Conference Coverage

Talazoparib Plus Enzalutamide Improves PFS for Metastatic Castration-Resistant Prostate Cancer

02/16/2023

Allison Casey ;

According to phase 3 interim data presented at the 2023 ASCO GU Symposium, talazoparib plus enzalutamide was superior to standard-of-care enzalutamide in imaging-based progression-free survival for patients with metastatic...

According to phase 3 interim...

02/16/2023

Oncology

Conference Coverage

Rucaparib Improved Survival Outcomes vs Docetaxel and Androgen Pathway Inhibitor Therapy Among Patients with Metastatic Castration-Resistant Prostate Cancer

02/16/2023

Allison Casey ;

According to phase 3 interim data presented at the 2023 ASCO GU Symposium, rucaparib improved radiographic progression-free survival vs either docetaxel or abiraterone/enzalutamide for patients with metastatic castration-resistant prostate...

According to phase 3 interim...

02/16/2023

Oncology

Conference Coverage

Darolutamide Plus ADT and Docetaxel As a New Standard of Care for Hormone-Sensitive Prostate Cancer

02/16/2023

Allison Casey ;

According to phase 3 trial data presented at the 2023 ASCO GU Symposium, darolutamide plus androgen-deprivation therapy and docetaxel improved the overall survival of patients with metastatic hormone-sensitive prostate cancer regardless of...

According to phase 3 trial data...

02/16/2023

Oncology

Conference Coverage

BXCL701/Talabostat As a Treatment Option for Refractory Metastatic Castration-Resistant Prostate Cancer of Small Cell Neuroendocrine Phenotype

02/16/2023

Allison Casey ;

According to phase 2a trial results presented at the 2023 ASCO GU Symposium, the oral small molecule inhibitor of dipeptidyl peptidases, BXCL701, showed promise among patients with refractory metastatic castration-resistant prostate cancer of...

According to phase 2a trial...

02/16/2023

Oncology

News

MRI Guidance for Stereotactic Body Radiotherapy Reduced Toxic Effects Among Patients With Prostate Cancer

02/10/2023

MRI-guided stereotactic body radiotherapy reduced the incidence of acute genitourinary and gastrointestinal toxic effects among patients with prostate cancer, compared to CT-guided therapy.

MRI-guided stereotactic body...

02/10/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology